Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their
design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were …

Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality.
Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above …

Gastrointestinal (GI) side-effects of chemotherapy are a debilitating and often overlooked
clinical hurdle in cancer management. Chemotherapy-induced constipation (CIC) and …

Intestinal mucositis remains one of the most debilitating side effects related to
chemotherapy. The onset and persistence of mucositis is an intricate physiological process …

Chemotherapy—induced gastrointestinal dysfunction is a common occurrence associated
with many different classes of chemotherapeutic agents. Gastrointestinal toxicity includes …

Diarrhoea induced by chemotherapy in cancer patients is common, causes notable
morbidity and mortality, and is managed inconsistently. Previous management guidelines …

Chemotherapy side effects (CSE) have a strong impact on patients' quality of life (QOL). To
assess patient perceptions of CSE, their impact on QOL and doctor–patient communication …

Purpose Diarrhea is one of the dose limiting toxicity of irinotecan. SN-38 is main irinotecan
metabolite responsible for diarrhea development, which is excreted in glucuronidated form …

Chemotherapy-induced diarrhea (CID) is a common and often severe side effect
experienced by colorectal cancer (CRC) patients during their treatment. As chemotherapy …

The toxicity of cancer chemotherapy is among the most important factors limiting its use.
Clear delineation and communication of benefits and risks is an essential component of …